


 Cite this: *RSC Adv.*, 2022, 12, 19703

# Gold nanoparticles decorated with ovalbumin-derived epitopes: effect of shape and size on T-cell immune responses†

 Elena A. Egorova,<sup>a</sup> Gerda E. M. Lamers,<sup>b</sup> Fazel Abdolapur Monikh,<sup>c</sup> Aimee L. Boyle,<sup>d</sup> Bram Slütter<sup>e</sup> and Alexander Kros<sup>\*a</sup>

Gold nanoparticles (GNPs) can be manufactured in various shapes, and their size is programmable, which permits the study of the effects imposed by these parameters on biological processes. However, there is currently no clear evidence that a certain shape or size is beneficial. To address this issue, we have utilised GNPs and gold nanorods (GNRs) functionalised with model epitopes derived from chicken ovalbumin (OVA<sub>257–264</sub> and OVA<sub>323–339</sub>). By using two distinct epitopes, it was possible to draw conclusions regarding the impact of nanoparticle shape and size on different aspects of the immune response. Our findings indicate that the peptide amphiphile-coated GNPs and GNRs are a safe and versatile epitope-presenting system. Smaller GNPs (~15 nm in diameter) induce significantly less intense T-cell responses. Furthermore, effective antigen presentation *via* MHC-I was observed for larger spherical particles (~40 nm in diameter), and to a lesser extent for rod-like particles (40 by 15 nm). At the same time, antigen presentation *via* MHC-II strongly correlated with the cellular uptake, with smaller GNPs being the least efficient. We believe these findings will have implications for vaccine development, and lead to a better understanding of cellular uptake and antigen egress from lysosomes into the cytosol.

 Received 13th May 2022  
 Accepted 28th June 2022

DOI: 10.1039/d2ra03027f

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## Introduction

The field of nanomedicine focuses on the use of nanoparticles to diagnose, monitor and treat diseases. Within this field, there is a particular focus on using nanoparticles as drug delivery vehicles or as vaccine platforms.<sup>1–5</sup> One reason that nanoparticles are suited to this purpose is that their nanometre size range imposes certain interactions between the particles and biological systems, for instance cellular uptake pathways, recognition by immunocompetent cells and clearance from circulation.<sup>6–8</sup> However, researchers have reported contradictory data on the effects of nanoparticle size and shape on immune response,<sup>2,9,10</sup> or effects of nanoparticle charge on cellular uptake, clearance, immune response,<sup>11</sup> and cytotoxicity.<sup>12–16</sup> Often, these reports do not provide sufficient information on the antigen loading or particle concentration. Also, they often

lack normalisation of the obtained results to a common parameter to aid comparison. Moreover, it is not always possible to find only one determinant parameter attributed to the biological effect of the studied nanoparticles. Parameters including size,<sup>17</sup> shape,<sup>2,18</sup> surface charge,<sup>12,19</sup> rigidity,<sup>6</sup> drug or antigen loading,<sup>1,2</sup> particle concentration,<sup>20,21</sup> total mass of nanoparticles,<sup>13,22</sup> and mean surface area available for contact<sup>2,20</sup> have all been proposed to affect the biological fate of studied particles.

Studying the effect of all these parameters on vaccine efficacy is an enormous undertaking. In order to make a new system suitable for screening the effects of the abovementioned parameters, a new approach is needed. This approach has to allow for thorough control over one parameter while other parameters, such as size, shape, surface charge, and/or surface chemistry are fixed. Gold nanoparticles (GNPs) can be synthesised in a range of sizes and shapes, therefore they are ideal for studying the shape and size dependency of a biological response. Through the use of different sizes and shapes of GNPs, the dependence of cellular uptake,<sup>18,21,22</sup> cytotoxicity,<sup>13,18</sup> and immune response<sup>23</sup> on physico-chemical properties can be studied. In addition, the surface chemistry of GNPs can be easily modified, and as a result, minimised toxicity and modulation of chronic inflammation risk induced by the antigen delivery particles are expected. Another advantage is that antigens are displayed on the GNP surface and cannot be compromised by non-specific interactions with the delivery

<sup>a</sup>Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, The Netherlands. E-mail: a.kros@chem.leidenuniv.nl

<sup>b</sup>Core Facility Microscopy, Institute of Biology, Leiden University, The Netherlands

<sup>c</sup>Environmental Biology, Institute of Environmental Sciences, Leiden University, The Netherlands

<sup>d</sup>Macromolecular Biochemistry, Leiden Institute of Chemistry, Leiden University, The Netherlands

<sup>e</sup>Leiden Academic Centre for Drug Research, Biotherapeutics, Leiden University, The Netherlands

† Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2ra03027f>



vehicle itself. For example, peptide-decorated liposomes can show partial encapsulation of the displayed peptides *via* engulfment into the lipid membrane.<sup>24</sup>

Here, we studied the effect of nanoparticle shape and size on antigen processing and presentation. For this, gold nanorods (GNRs) of 40 by 15 nm in size and spherical GNPs of 15 and 40 nm in diameter were synthesised. The choice of these sizes was dictated by multiple lines of evidence showing that nanoparticles of 40–50 nm in diameter exhibit more efficient cellular uptake<sup>7,21</sup> and immune response compared to other sizes.<sup>29</sup> GNPs with a diameter of 15 nm are often used in literature and were chosen to serve as a reference for GNRs' width.<sup>3,17,19,25</sup> GNRs were introduced to elucidate the effect of shape and their length matched the diameter of the larger GNPs. Incorporation of two spherical particle sizes matching the GNRs dimensions was intended to decouple the effects of shape and size.

A protective coating on the gold surface is required to maintain particle stability in biological media, to prevent aggregation, and to eliminate potential cytotoxicity.<sup>12,19,25–28</sup> It was previously shown that, depending on the aggregation state, endocytosis pathways may vary for the same nanoparticle formulation.<sup>29</sup> In addition to stabilizing molecules, antigens can be attached to the GNP surface to modulate antigen processing in dendritic cells (DCs).<sup>1</sup> Using a common stabilizing molecule for the three selected nanoparticle types results in an identical surface chemistry allowing for a fair comparison of the elicited cellular responses. Previously, we reported the use of thiolated peptide amphiphiles as stabilisers for both GNPs and GNRs.<sup>30,31</sup> These coatings insulate the gold surface, prevent particle aggregation under harsh conditions (up to 3 M NaCl, or 1 M competing thiols), and provide GNPs with surface chemistry described as “protein-like”.<sup>32</sup> Published data suggest that biologically active moieties displayed on the surface of peptide-capped GNPs preserve their biological function and their availability,<sup>32–35</sup> and that GNPs do not impair immune functions of DCs or B cells.<sup>19,26,27</sup> Unlike most other metallic nanoparticles, GNPs do not give rise to reactive oxygen species (ROS) *in vitro*, hence oxidative stress and ROS-related cytotoxicity are less common.<sup>25</sup>

In this study, 15 nm and 40 nm GNPs and 40 by 15 nm GNRs were coated with a stabilizing peptide amphiphile,<sup>30</sup> referred to as the **base** molecule. Two more peptide amphiphiles were extended with model epitopes derived from the chicken ovalbumin (OVA) protein (OVA<sub>257–264</sub> or OVA<sub>323–339</sub>). The bioactive peptide amphiphile coupled to OVA<sub>257–264</sub>, the major histocompatibility complex class I (MHC-I) restricting epitope, was abbreviated as **1**, and the peptide amphiphile coupled to OVA<sub>323–339</sub>, the major histocompatibility complex class II (MHC-II) restricting epitope, was denoted as **2**.

Immunogenicity of the epitope-decorated GNPs and GNRs was studied using cells derived from the ovalbumin transgenic OT-I and OT-II mice. T cells of these mice express T-cell receptors (TCRs) that are specific for either OVA<sub>257–264</sub> (OT-I) or OVA<sub>323–339</sub> (OT-II) epitopes and pair with either CD8 or CD4 coreceptors.<sup>36</sup> ‘Splitting’ the immune response into two components (OVA<sub>257–264</sub> modulates the cytotoxic T-cell response, while OVA<sub>323–339</sub> – the helper T-cell response)

should provide more clarity as to how the immune system reacts to more complex antigens, depending on their size and shape.

The proposed system can be used as a screening system for evaluation of parameters like epitope sequence, epitope display density, size and shape of the carrier nanoparticle, as well as the charge. With a single mixture of the base and epitope-bearing amphiphiles it is possible to decorate a wide range of GNPs (spheres in the 15–100 nm range and GNRs, according to our previous studies). The procedure takes <2 hours and yields highly stable conjugates in physiological conditions. These GNPs are easily detected, quantified, and accurately dosed based on their optical properties. This system allowed us to thoroughly investigate cytotoxic and T-helper immune responses. Our findings suggest that antigen egress from lysosomes is related to the carrier nanoparticle size or volume. We believe these findings will have implications for vaccine development, and lead to a better understanding of cellular uptake and antigen egress from lysosomes into the cytosol.

## Results and discussion


### Characterisation of peptide–gold conjugates

In order to maintain identical surface chemistry, GNPs of different shape and sizes were coated with a mixture comprising 9 molar parts of the **base** peptide amphiphile and 1 molar part of the active peptide amphiphile **1** or **2** (Scheme 1). The **base** composition was inspired by our previous work and comprised a double thiolated C<sub>11</sub> chain conjugated to a KVVVAAEEEE peptide domain *via* the N-terminus and the lysine side-chain.<sup>30</sup> The thiol group enabled coordination of the ligands to the gold surface *via* an Au–S bond. The active peptide amphiphiles comprised a single thiolated C<sub>11</sub> chain conjugated, *via* the N-terminus, to a peptide with the sequence V<sub>3</sub>A<sub>3</sub>E<sub>3</sub>, while the epitopes were coupled to the C-terminus of this peptide sequence *via* a PEG<sub>4</sub>-spacer. Epitope sequences corresponded to OVA-derived T-cell epitopes (SIINFEKL, OVA<sub>257–264</sub>, is an MHC-I binding epitope, and ISQAVHAAHAEINEAGR, OVA<sub>323–339</sub>, is an MHC-II binding epitope). The active peptides **1** and **2** were conjugated to a single alkyl chain instead of a double chain to aid solubility of the resulting compounds.

As-synthesised citrate-stabilised GNPs and CTAB-protected GNRs were characterised with dynamic light scattering (DLS, for GNPs only), ultraviolet-visible spectroscopy (UV-vis), and transmission electron microscopy (TEM) to confirm their size and dispersity (Table 1, Fig. 1 and S1†). Due to their rod-like shape, GNRs were not analysed by DLS, instead only UV-vis spectroscopy and TEM data were collected.

Upon modification with the peptide amphiphiles, a slight increase in the hydrodynamic size for all peptide–gold conjugates was observed with DLS. The incorporation of the extended sequences **1** or **2** (10 mol%) into the base peptide shell did not lead to agglomeration of GNPs (Fig. 1; for intensity size distributions see Fig. S1†). The UV-vis spectroscopy supported these findings, since the absence of plasmon band broadening for **15-base**, **15-1**, and **15-2** relative to **15-citrate** indicated that no aggregation occurred after the peptide coatings were applied (Fig. 1A). The same was true for 40 nm GNPs and GNRs. The





**Scheme 1** Schematic representation of the shell composition (**base** and epitope-bound peptide amphiphiles 1 and 2) used to stabilise GNPs and GNRs. **Base** was mixed with either 1 or 2 at a 9 : 1 molar ratio to form shells around different GNPs and to provide near-identical surface chemistries.

**Table 1** GNPs size characteristics before/after modification based on TEM imaging and DLS data

Sample	15 nm GNPs	40 nm GNPs
Av. size of the core (TEM)	15.0 ± 1.4 <sup>a</sup>	43.5 ± 3.3
<b>Citrate</b>	15.5 ± 0.2	40.4 ± 0.5
<b>Base</b>	26.8 ± 0.3	50.8 ± 0.1
<b>1</b>	25.9 ± 0.3	50.8 ± 0.8
<b>2</b>	26.6 ± 0.6	54.3 ± 0.2

<sup>a</sup> Standard deviation. To determine the core size, citrate-stabilised GNPs were imaged using TEM. The size of peptide amphiphile-coated GNPs was determined using DLS. Both average size and mean hydrodynamic diameter are given in nm. Peptide amphiphile-coated samples were prepared in PBS (pH 7.2).

small (1–7 nm) red-shift of the plasmon band is related to substitution of citrate or CTAB on the gold surface with other molecules, which leads to a change in the dielectric constant.<sup>37</sup> Since neither DLS (Fig. S1A and B†) nor TEM imaging (Fig. 1B) indicated aggregation, the peptide-coated GNPs and GNRs were presumed to be monodisperse. TEM imaging revealed particle clustering, which can be explained by so-called drying effects during sample deposition on a TEM grid. This clustering was also facilitated by the presence of salts, since all tested samples were prepared in PBS (pH 7.2), which meant that upon drying the local concentration of salt increased significantly to cause the observed clustering.<sup>30</sup> Zeta potential values of as-synthesised citrate-capped GNPs and amphiphile-coated GNPs showed that particles had a negative surface charge (up to –30 mV, Fig. S1C–E†). A slight deviation of surface charge for GNPs coated with 1 and 2 from the samples coated with the **base** sequence was explained by a slight change in the surface chemistry when the active peptides were incorporated. The GNRs showed a zeta potential change from positive to negative, indicative of CTAB displacement from the GNR surface by the peptide amphiphiles (Fig. S1E†). A negative net charge for peptide amphiphile-coated GNPs and GNRs is advantageous: negatively charged particles cause less cytotoxicity compared to

positively charged counterparts, and better cellular uptake than neutral nanoparticles.<sup>7</sup>

TEM analysis revealed the presence of well-defined peptide shells surrounding the gold core (Fig. 1B). The shell around the GNPs and GNRs ensured that particles were separated from each other with the interparticle distance corresponding to the shell thickness. The thickness of the shells (<5 nm) is in agreement with a peptide-amphiphile monolayer around the particles.<sup>30</sup> Notably, in the TEM images there was no obvious difference in the shell thickness for samples with the functional peptides 1 or 2 incorporated, possibly due to a low epitope display density.

According to our previous work, GNPs coated with these amphiphilic molecules are highly stable at elevated salt concentrations and are resistant towards thiols,<sup>30</sup> thus the GNPs and GNRs presented in this work were expected to be stable under biologically relevant conditions.

### Number concentration and epitope dosage

To study biological effects elicited by nanoparticles of different size and shape, a defined set of shared parameters should be adopted to enable comparison. It can be particle number, particle surface area available for interaction,<sup>2,20</sup> or drug/active molecule loading/dosage.<sup>21,38</sup> Unfortunately, reports with a normalisation used to truly define the effect of a particle parameter (*e.g.* of an antigen loading rather than particle mass) on a biological response are scarce.<sup>2,13,22</sup> In order to calculate the above-mentioned parameters, inductively coupled plasma mass spectrometry (ICP-MS) was used. This technique has been previously used to determine the thiol-containing ligand coverage on GNPs,<sup>39</sup> as well as metal content in cells and tissues.<sup>2,13,17,19,20,25,40</sup>

Peptide amphiphile-coated GNPs and GNRs were digested in *aqua regia* and analysed with ICP-MS to determine gold mass concentration, which was later translated to particle number concentration (Fig. S2†). The measured concentrations were linked to the optical density (OD) of the GNP or GNR suspension (Table 2). This enables accurate dosing of the GNP and GNR






Fig. 1 Sample characterisation of the GNPs used in this study: (panel A) UV-vis spectra for coated 15 nm GNPs, 40 nm GNPs, and GNRs; (panel B) TEM images of the corresponding peptide-gold conjugates. Modified samples were prepared in PBS (pH 7.2). Scale bars: 50 nm for 15-base, 15-1, and 15-2; 100 nm for others. Staining – 1% uranyl acetate. The visible shells are the peptide coatings.

samples according to their OD, acquired with UV-Vis spectroscopy. We determined that a GNP suspension with an OD = 1.0 corresponded to number concentrations within the  $10^{11}$ – $10^{12}$  particle per mL range regardless of the applied coating, which is in agreement with data for citrate-capped GNPs provided by Sigma Aldrich (<https://www.sigmaaldrich.com/NL/en/technical-documents/technical-article/materials-science-and-engineering/biosensors-and-imaging/gold-nanoparticles>).

Moreover, GNPs with the same gold core but different peptide amphiphile coatings showed similar normalised number concentrations (Table 2), signifying that the employed coating strategy did not result in different optical properties arising from the applied stabiliser. Furthermore, incorporation of

10 mol% of the epitope-displaying functional peptides 1 or 2 did not affect the optical properties either.

To quantify the epitope dosage, another peptide amphiphile was synthesised. Mercapto-undecanoyl- $V_3A_3E_3G_5WG$  (denoted as **W**, see Scheme S1†) was composed of a single  $C_{11}$  alkyl chain, the same peptide domain as 1 or 2, and a single Trp (tryptophan, W), conjugated *via* a Gly<sub>5</sub> spacer (glycine, G). GNPs and GNRs were coated with 9 molar parts of the **base** amphiphile and 1 molar part of **W**. From the amount of the bound **W** together with the known relationship between OD and number concentration, the epitope loading was calculated (Table 2).

Due to the high relative surface area and high number concentration, 15 nm GNPs carry a significant epitope load,

Table 2 Normalised number concentrations and epitope dosage of GNPs and GNRs

	Normalised number concentration, <sup>a</sup> particles per mL			Epitope concentration, $\mu\text{M}$		
	15 nm GNPs	40 nm GNPs	GNRs	15 nm GNPs	40 nm GNPs	GNRs
Base	$4.03 \times 10^{12}$	$1.49 \times 10^{11}$	$3.54 \times 10^{11}$	n/a	n/a	n/a
1	$3.83 \times 10^{12}$	$1.25 \times 10^{11}$	$4.06 \times 10^{11}$	2.6	0.4	0.6
2	$3.46 \times 10^{12}$	$1.46 \times 10^{11}$	$3.93 \times 10^{11}$	2.4	0.5	0.6

<sup>a</sup> The obtained mass concentrations were divided by the mass of one particle and normalised to  $\text{OD}_{\text{LSPR}} = 1.0$ . Samples were prepared in PBS (pH 7.2). For normalised mass concentrations and areas available for contact, see Fig. S2B,C. n/a – not applicable.



while carrying a low number of epitopes per particle. Consequently, 40 nm GNPs had a lower number concentration but higher antigen load per particle. Due to their shape, GNRs have a higher relative surface area and number concentration than 40 nm GNPs. In order to study a dose – response effect arising from GNP shape and size for both epitopes, the  $\approx 5\text{--}500$  nM concentration range in the cell exposure medium equivalent to the epitope content displayed on the gold surface was used for further studies.

### Cytotoxicity of coated GNPs and GNRs

An *in vitro* cytotoxicity test was performed prior to studying immune response, to ensure that the peptide amphiphile-coated GNPs and GNRs were not harmful to cells. BMDCs were used in this assay for two reasons. BMDCs, like other types of dendritic cells (DCs), are antigen-presenting cells most likely to first encounter pathogens. Moreover, the *ex vivo* assay using transgenic ovalbumin mice (OT-I and OT-II) to probe the immunogenicity requires DCs treatment as the first step.

According to an Lactate dehydrogenase (LDH) assay, the observed peptide-gold nanoconjugate cytotoxicity was found to

be  $<10\%$  after 4 hours of exposure and  $<20\%$  after 24 hours for all tested GNPs and GNRs (negative control = PBS, 0% cytotoxicity; positive control = assay lysis buffer, 100% cytotoxicity, Fig. 2 and S3†). This was true for all particle concentrations tested. Notably, 15-base showed the highest toxicity, most likely attributed to their high number concentration.<sup>20,22</sup> On average, cytotoxicity increased after 24 hours compared to the 4 hour exposure for all tested particles. However, there was no statistically significant difference between the cytotoxicity demonstrated by GNPs compared to GNRs after 24 hours.

This data is consistent with published results of different GNP samples in different cell types. PEGylated GNPs and GNRs were shown to have a limited effect on LDH release ( $<20\%$  after 24 hour exposure)<sup>14,25</sup> and cell death ( $<15\%$  after 24 hour exposure).<sup>1,17,19,25</sup> According to Fytianos *et al.* polymer-coated GNPs (15 nm in diameter) did not induce cell death independent of the surface charge,<sup>19</sup> while Bhamidipati *et al.* reported that the surface chemistry contributes towards cytotoxicity, but not the shape when spherical (20 nm in diameter), rod-like (53 by 23 nm), and star-like (63 nm) GNPs were compared.<sup>25</sup> Kang *et al.* reported that neither of 10, 22, or 33 nm OVA protein-coated GNPs induced cytotoxicity.<sup>17</sup> It has also been reported that PEGylation of GNRs abolishes cytotoxicity typical for CTAB-stabilised GNRs.<sup>25,28</sup> Additionally, changing the surface chemistry by addition of a bioactive peptide did not induce acute cytotoxicity in BMDCs.

### Cellular uptake of OVA-decorated GNPs and GNRs by BMDCs

Cellular uptake defines the antigen fate inside the cell and is crucial for establishing a link between the evoked immune reaction and the nanoparticle type. Cellular uptake of peptide-gold nanoconjugates by BMDCs was quantified using ICP-MS and the subcellular localisation of endocytosed GNPs and GNRs was visualised with TEM. For this study, BMDCs were differentiated from bone marrow progenitor cells and exposed to epitope-bearing GNPs and GNRs for 4 hours.

GNPs and GNRs were found inside subcellular vesicles but not dispersed in the cytosol or other organelles apart from lysosomes (Fig. 3 and S4†). There was no apparent difference in nanoparticle distribution as a function of peptide amphiphile composition. However, the appearance of these vesicles and number of entrapped particles depended on the nanoparticle core shape and size. For example, 40-1 and 40-2 showed fewer particles per vesicle ( $<10$ ) than 15-1, 15-2, Rods-1, or Rods-2. The appearance of vesicles entrapping 40-1 and 40-2 may suggest a different endocytosis pathway than in the case of GNRs and 15 nm GNPs. The volume of most of these vesicles was very low and particles appeared to be “encased” in the endosomal membrane. For 15 nm GNPs and GNRs, the vesicles looked similar: larger vesicles with high particle numbers ( $>10$ ) dominated, although small vesicles ( $<100$  nm) containing fewer particles were also observed.

The type and function of these vesicles could not be determined from TEM analysis, but these vesicles could be divided into several groups based on their size and appearance. Small vesicles with a low number of particles inside are most likely to





Fig. 2 Cytotoxicity profiles for the peptide-coated GNPs and GNRs at different time points (A) 4- and (B) 24 hour exposure times. Cytotoxicity was evaluated in BMDCs ( $20 \times 10^3$  cells per well) with the LDH release assay ( $N = 2, n = 3$ ) at the highest concentration used for each experimental group (15 nm GNPs –  $\sim 2.0 \times 10^{11}$  particles per mL; 40 nm GNPs –  $\sim 1.0 \times 10^{10}$  particles per mL; GNRs –  $\sim 5.0 \times 10^{10}$  particles per mL in the cell exposure medium). PBS was used as the negative control (0% cytotoxicity) and assay lysis buffer was used as the positive control (100% cytotoxicity). Error bars indicate standard deviations calculated using GraphPad Prism software. ANOVA (one-way) showed there was no significant difference inside the test groups ( $p \geq 0.05$ ). For the cytotoxicity profiles for more nanoparticle concentrations see Fig. S3.†





**Fig. 3** GNPs uptake by BMDCs (A–F) studied using TEM imaging and (G–I) quantified with ICP-MS. Localisation of GNPs and GNRs inside BMDCs sections after a 4 hour incubation was studied using TEM: (A) 15-1; (B) 40-1; (C) Rods-1; (D) 15-2; (E) 40-2; and (F) Rods-2. Scale bars: 500 nm (A,C,D and F) or 1  $\mu$ m (B and E). A representative image of a DC treated with PBS, low magnification images and their analysis can be found in Fig. S4 and S5.† Error bars in (G–I) indicate standard deviations and were calculated in GraphPad Prism software, as well as the results significance (unpaired *t*-test; ns = not significant,  $p \geq 0.05$ ; \* =  $p$  within 0.01–0.05).

be endocytic vesicles that are to be fused with endosomes to start the endo-lysosomal pathway.<sup>7,8</sup> Reformed endosomes undergo a maturation process and subsequently fuse with lysosomes. Lysosomes can be distinguished by their darker

contents in the TEM images.<sup>41</sup> Reformed lysosomes perform antigen digestion, which is crucial for antigen presentation through MHC-epitope interactions. Analysis of the TEM images for the vesicles' dimensions and number of entrapped particles

**Table 3** Quantitative analysis of TEM images for number of entrapped GNPs and GNRs

Sample	Total vesicle count	One NP <sup>a</sup> per vesicle, %	≤10 NPs per vesicle, %	>10 NPs per vesicle, %
15-1	137	15.3	48.9	35.8
40-1	177	65.5	34.5	0
Rods-1	200	13.0	74.0	13.0

<sup>a</sup> NP – nanoparticle.



showed differences between the different GNPs (Table 3 and Fig. S5† shows analysis for particles decorated with 1, OVA<sub>257–264</sub>). It should be noted that this analysis was based on a vesicle part restricted to a thin section (70 nm thickness), but not on a vesicle's full volume. There were no vesicles with more than eight 40-1 particles inside and 65.5% of the vesicles contained only one particle ( $n = 177$ ). Small vesicles (40–120 nm) with low particle numbers (<6) are likely to be endocytic vesicles. On the other hand, 15-1 and R-1 showed a different behaviour. Only 15.3% of vesicles ( $n = 137$ ) contained one 15-1 particle, while for R-1 this value was 13.0% ( $n = 200$ ). At the same time, vesicles with  $\leq 10$  entrapped particles were moderately present in BMDCs exposed to 15-1 (48.9%), but formed the majority in the case of R-1-exposed cells (74.0%). 15-1 showed a variety of endocytic vesicles: vesicles with one particle inside or ones formed by interactions between the plasma membrane and multiple particles. This suggests that multiple endocytosis pathways are involved for 15-1 uptake. Also, nanoparticles were seen in the cytosol, but these events were rare (<0.5% for all samples).

These findings indicate that different endocytosis pathways might be involved in GNP/GNR uptake. Published data suggests the following pathways for coated GNPs and GNRs: receptor-mediated and macropinocytosis for GNPs within the 15–40 nm size range;<sup>21,38</sup> and receptor-independent<sup>22</sup> and a combination of clathrin-/caveolae- and lipid raft-mediated pathways for GNRs.<sup>18</sup> Ding *et al.* also reported that endocytosis pathways for GNPs can be influenced through their surface chemistry.<sup>22</sup> Solely based on the TEM images it was not possible to distinguish what specific endocytosis pathways peptide amphiphile-coated GNPs and GNRs employ. To address this, more uptake studies focusing on the use of endocytosis inhibitors should be conducted.<sup>18,22,42</sup>

In order to study the immunological impact of nanoparticles of different size and shape, it was important to determine the gold content per cell. Since quantification of cellular uptake based on the TEM images would not be reflective of the entire cell population, ICP-MS was used to calculate gold content per cell. To make a fair comparison, the number of added nanoparticles was fixed to the gold core size, meaning the same number of 15-1 or 15-2 was added.

After the 4 hour exposure time 15-1 and 15-2 were taken up by BMDCs to the same extent ( $123 \times 10^3$  versus  $121 \times 10^3$  particle per cell), and 40 nm GNPs and GNRs showed the same trend (Fig. 3G). This suggests that altering the active peptide in the shell composition did not have an effect on GNPs or GNRs uptake by BMDCs. It should be noted that 15 nm and 40 nm GNPs, although taken up in the same mass (in the range of 3.6–4.0 pg per cell), significantly differed in number ( $\sim 25\times$  times more for 15 nm GNPs) and delivered total surface area ( $\sim 3\times$  times more for 15 nm GNPs, Fig. 3H and I). The surface area available for contact that was delivered into the cells could be correlated to the number of delivered antigens and it decreased in the following order: 15 nm GNPs > GNRs > 40 nm GNPs. In our study epitope-decorated 15 nm GNPs could deliver  $\sim 3\times$  times more antigens than 40 nm GNPs and  $\sim 2\times$  times more than GNRs.

### Effect of size and shape on CD4<sup>+</sup> and CD8<sup>+</sup> T cell proliferation

OT-I and OT-II transgenic mouse lines express T-cell receptors (TCR) specific to OVA-derived epitopes, respectively OVA<sub>257–264</sub> and OVA<sub>323–339</sub>.<sup>36</sup> BMDCs obtained from these mice were exposed to the epitope-decorated GNPs and GNRs. BMDCs endocytosed the nanoparticles and antigens were to be cleaved from the gold surface and presented back to the surface of the BMDCs. After 4 hours of exposure, required for antigen processing and presentation to take place, the GNPs were removed, isolated CD8<sup>+</sup> (OT-I, samples coated with 1) or CD4<sup>+</sup> (OT-II, samples coated with 2) T cells stained with 5(6)-carboxy-fluorescein diacetate *N*-succinimidyl ester (CFSE) were added to the activated BMDCs, and the cells proliferated for 72 hours. The degree of T-cell activation was determined with flow cytometry using CD25 gated *versus* CFSE stain signals (CD25<sup>+</sup>CFSE<sup>low</sup> T-cell subset, for gating strategy see Fig. S6†).

The assays revealed striking effects of size and shape on the ability of GNPs to induce T-cell mediated responses (Fig. 4).

Based on the dose response curves for 40 nm GNP and GNRs, the particle shape seems to significantly affect CD4<sup>+</sup> T-cell expansion, with GNRs requiring a substantially lower antigen




Fig. 4 Dose-response curves reflecting proliferation rates for (A) OT-II mice derived CD4<sup>+</sup> cells and (B) OT-I mice derived CD8<sup>+</sup> cells in response to OVA epitope-decorated GNPs (15 and 40 nm in diameter) and GNRs. % of proliferating cells was calculated from the CD25<sup>+</sup>CFSE<sup>low</sup> T-cell subset (for gating strategy, see Fig. S6†). Epitope concentration (nM) presented here is the final epitope concentration in the cell exposure medium. The gray line shows the positive controls, free epitopes. Three independent experiments were conducted for each GNP preparation ( $N = 3$ ,  $n = 3$ ), and a representative example is shown here. Error bars indicate standard deviations. Data sets were fitted into a dose-response curve using GraphPad Prism software.



dose to induce OT-II proliferation. Particle size also exhibited a significant impact as 15 nm GNPs were the least effective carrier system. The difference between the behaviour of **R-2** and **40-2** can be explained by the MHC-II pathway employed to present processed antigens back to the plasma membrane. MHC-II loads antigens directly inside lysosomes.<sup>43</sup> Following this idea, **Rods-2** were expected to outperform **40-2**, since the former delivers more antigens into cells (Fig. 3I).

Nonetheless, the CD8<sup>+</sup> T-cell response was not that trivial to interpret. Similarly to CD4<sup>+</sup> T cells, 15 nm GNPs appeared to be the inferior delivery system to induce CD8<sup>+</sup> T-cell response, with the 15 nm GNPs showing a clear shift in dose response compared to GNRs. **40-1** was the only formulation that did not show a typical S-shaped dose – response curve: proliferation of CD8<sup>+</sup> T cells was suppressed at higher **40-1** concentrations. This suggests that the MHC-I processing pathway is inhibited at a higher concentration of the 40 nm GNPs. MHC-I is supplied with antigens present in the cytosol.<sup>43</sup> Egress of antigens from lysosomes into the cytosol is a complex process that is not yet well understood.<sup>44</sup>

As we already eliminated the possibility of cytotoxicity at higher **40-1** concentrations (Fig. 2), we next assessed whether the effect of **40-1** on the MHC-I processing pathway was indeed

dose-dependent. To test this, BMDCs were exposed for 4 h to the various nanoparticle concentrations and the amount of OVA<sub>257–264</sub> presented on MHC-I (H2-Kb) was quantified with flow cytometry. In contrast to **15-1** and **R-1**, with a decreasing concentration of **40-1**, an increase in antigen presentation was detected (Fig. S7 and S8†). Moreover, the level of OVA<sub>257–264</sub> presentation achieved with **40-1** was higher than that induced by an equivalent amount of whole OVA protein (Fig. S9†). However, the used antibody against the whole MHC-I complex was clearly more sensitive to processing and presentation of free peptide or amphiphile **1** rather than larger constructs, as they showed clear dose-dependent profiles.

'Splitting' the T-cell immune response into two components (cytotoxic and T-helper) highlighted several aspects. There is potentially a size threshold below which BMDCs, and hence T cells, only become activated when a very high antigen loading is applied (Fig. 4). Furthermore, CD4<sup>+</sup> T-cell activation (T-helper component) is sensitive to the size or shape of a carrier particle and correlates to cellular uptake and the number of delivered antigens. MHC-I processing, and therefore CD8<sup>+</sup> T-cell activation (cytotoxic component), does not seem to be directly linked to the amount of material that is taken up, but is influenced by the size and/or shape of carrier nanoparticles. These




Fig. 5 Activation of BMDCs 24 h post exposure to epitope-decorated GNPs and GNRs through cytokine release (A) IL-12 and (B) IL-1 $\beta$  or cellular receptor upregulation of (C) CD80 and (D) CD86. The different nanoparticles were used in the following equivalent concentrations: 15 nm GNPs – equivalent to ~500 nM epitope; 40 nm GNPs – equivalent to ~125 nM epitope; GNRs – equivalent to ~300 nM epitope. For comparison, OVA<sub>257–264</sub> was added to study cellular receptor upregulation (200 nM in the cell exposure medium). Significance of the datasets mean values was determined through comparison to the negative control (PBS or supplemented DMEM, \* –  $p$ -value  $\leq$  0.05, \*\* –  $p$ -value  $\leq$  0.01, \*\*\* –  $p$ -value  $\leq$  0.001, \*\*\*\* –  $p$ -value  $\leq$  0.0001). For more data points, see Fig. S10–S15.†



aspects should be taken into account when a new vaccine platform is being developed and one type of immune response is preferred over the other.

### Effect of size and shape on BMDCs activation

In order to obtain additional details on the performance of GNPs and GNRs, activation of BMDCs was studied. Interleukin 12 (IL-12) and interleukin 1 beta (IL-1 $\beta$ ) provide information on activation of DCs by particulate formulations.<sup>2,3,19,45,46</sup> For this, BMDCs were exposed to epitope-decorated GNPs and GNRs for 24 hours and the cytokine levels were determined with an enzyme-linked immunosorbent assay (ELISA) (Fig. 5 and S10–S12 $\dagger$ ).

IL-12 is a cytokine secreted by activated DCs in response to Pathogen Recognition Receptor stimulation and promotes differentiation of naïve T cells into T helper1 cells and therefore production of IFN- $\gamma$ .<sup>46,47</sup> IL-12 also mediates enhancement of CD8<sup>+</sup> cytotoxic T-cell activity. Compared to the PBS negative control, only GNRs showed significant levels of IL-12 secretion (Fig. 5A). All tested concentrations of 15-1 and 15-2 failed to induce IL-12 secretion, which indicates that 15 nm GNPs indeed do not activate BMDCs, although they showed potential in delivering high antigen loads (Fig. 3). On the other hand, 40 nm GNPs in high concentrations had almost no impact, while a low number concentration of 40-2 was as effective as high number concentrations of GNRs. GNRs showed a concentration-dependent effect on IL-12 secretion. Additionally, neither of the employed peptide amphiphiles induced IL-12 secretion when administered without the nanoparticles (Fig. S11 $\dagger$ ). Therefore, our peptide amphiphiles cannot be considered to activate BMDCs, which is the case for other peptide amphiphiles.<sup>45</sup> Previously, protein-coated GNPs (40 nm in diameter) and gold nanocubes (40 by 40 nm) were reported to induce IL-12 secretion, but not smaller GNPs (20 nm in diameter) or GNRs.<sup>2</sup> Our data therefore supports the assertion that small GNPs do not induce IL-12 secretion, but contradicts the previous report as GNRs are capable of inducing IL-12 secretion in this study.

Additionally, the capacity of epitope-decorated GNPs and GNRs to induce inflammation was studied through IL-1 $\beta$  secretion. None of the tested particles induced significantly elevated levels of IL-1 $\beta$  compared to the negative control (PBS), indicating that the observed activation of BMDCs did not follow an inflammasome-mediated pathway (Fig. 5B and S12 $\dagger$ ). These findings are in agreement with previous studies using spherical GNPs: irrespective of the GNP size or coating, they did not induce inflammasome formation.<sup>2,19</sup> There is no consensus between the results presented here and published data on GNRs. Depending on the coating, GNRs were reported to cause significant levels of IL-1 $\beta$  secretion. For example, this was observed for GNRs coated with the West Nile virus envelope protein, while spherical and cubic GNPs did not induce IL-1 $\beta$  secretion.<sup>2</sup> GNRs coated with recombinant Sm29 proteins derived from *Schistosoma mansoni* also induced high levels of IL-1 $\beta$ , however CTAB-stabilised or cysteamine-stabilised GNRs did not.<sup>48</sup> Furthermore, PEGylated GNRs also did not induce IL-1 $\beta$ .<sup>28</sup>

Next, upregulation in cellular markers of BMDCs under treatment with OVA<sub>257–264</sub>-decorated particles was studied. Both CD80 and CD86 are necessary for T-cell activation and survival through co-stimulation with CD28 expressed on T cells.<sup>47,49</sup> Both receptors are already upregulated on BMDCs due to their handling during the culture procedure, which is reflected in the negative control, DMEM (Fig. S13–S15 $\dagger$ ). With respect to the negative control, only 40-1 showed an elevated CD80 level (Fig. 5C and S14 $\dagger$ ). CD86 was more readily activated by 40-1 and less by Rods-1, but not by 15-1 or free OVA<sub>257–264</sub> (Fig. 5D and S15 $\dagger$ ). Enhancement provided by 40-1 was almost double compared to the effect of Rods-1, and showed a dose dependence. This may be explained by the fact that for this assay we used  $50 \times 10^3$  cells versus previously used  $20 \times 10^3$  cells. This assay helped to clarify the effect of 40 nm GNPs on BMDCs activation: most likely, suppressed secretion of IL-12 (Fig. 5A) and CD8<sup>+</sup> T-cell proliferation (Fig. 4A) at higher particle concentrations could be attributed to BMDCs overstimulation. Moreover, when BMDCs were exposed to the whole OVA protein, no upregulation in CD80 or CD86 was detected (Fig. S17 and S18 $\dagger$ ). The same was true for peptide amphiphiles 1, 2, and base. This way, the observed effect of 40-1 can be attributed to the presence of GNPs.

The results of CD80 and CD86 activation of BMDCs are consistent with previously reported data: 33 nm GNPs coated with the whole OVA protein were shown to induce greater upregulation in both CD80 and CD86 expression than 10 or 22 nm GNPs coated with OVA.<sup>17</sup> Additionally, antigen-coated GNRs were able to induce simultaneous upregulation of CD86, MHC-I, and MHC-II.<sup>48</sup>

Thus, despite the potential of 15 nm GNPs to deliver higher doses of antigens than 40 nm GNP and GNR counterparts, they failed to activate BMDCs. GNRs were capable of delivering significant antigen loads and caused concentration-dependent activation of BMDCs. 40 nm GNPs were the only particles capable of inducing significant upregulation in BMDCs activation markers. None of the tested particles caused inflammation. These results are in agreement with previously published studies for GNPs, however contradict published data for GNRs.

In summary, our study showed that peptide-gold nanoconjugates comprising a gold core of differing shape and size indeed have an impact on BMDC activation and subsequent T-cell expansion. “Splitting” the two T-cell responses showed two different outcomes for two different pathways: there was no single common shape or size that would be unconditionally beneficial for both T-cell responses.

## Conclusions

Peptide-gold nanoconjugates comprising a gold core of differing shape and size (15 and 40 nm in diameter, and rods of 40 by 15 nm) and a peptide shell did not cause cytotoxicity in BMDCs. Cellular uptake of GNPs and GNRs by BMDCs was governed by the gold core parameters, irrespective of the displayed antigen. Core particle parameters such as shape and size indeed have an impact on BMDC activation and subsequent T-cell expansion. Size seemed to play a major role, as the 40 nm



GNP showed superior performance in respect to the 15 nm GNPs in every aspect. The shape of GNPs had an effect on the CD8<sup>+</sup> T-cell response with the 40 nm GNPs being significantly more effective than the GNRs, despite a lower epitope dose delivered. However, these two samples showed very similar CD4<sup>+</sup> T-cell responses. The differences in immune responses were not governed by the total NP uptake but by the intracellular routing of the particles (MHC-I or MHC-II pathway).

## Experimental

### Materials

All chemicals were purchased from Sigma-Aldrich unless stated otherwise. CTAB ( $\geq 99\%$ , H6269) and HAuCl<sub>4</sub> × 3H<sub>2</sub>O (49% Au basis, G4022) were purchased from Sigma-Aldrich. Silver nitrate (99.999%) and Oxyma Pure were purchased from Carl Roth GmbH. TFA, piperidine, DMF, DCM, methanol, and acetonitrile were purchased from Biosolve. TEM grids (Formvar/Carbon, 200 mesh, on copper support) were purchased from Electron Microscopy Sciences. FCS, penicillin/streptomycin mixture, L-glutamate, DMEM and RPMI 1640 cell culture media were purchased from Lonza. Mouse granulocyte-macrophage colony-stimulating factor (GM-CSF) was purchased from PeproTech. CD4<sup>+</sup> and CD8<sup>+</sup> isolation kits (*via* MACS magnetic separation) were purchased from Miltenyi Biotech. LDH leakage assay (LDH-Cytox™ Assay Kit) and the specific antibody against the whole MHC-I/OVA<sub>257–264</sub> complex (PE anti-mouse H-2Kb bound to OVA<sub>257–264</sub> antibody, Kb-OVA<sub>257–264</sub>) were purchased from Biolegend. ELISA standards (IL-12 and IL-1β) and antibodies, TMB substrate, as well as immunostaining antibodies were purchased from eBioscience.

### Gold nanoparticles synthesis

Spherical particles (GNPs) of 15 and 40 nm in diameter were synthesised *via* citrate reduction and overgrowth as described elsewhere.<sup>30</sup> The average size of the GNPs in suspension was analysed using dynamic light scattering (DLS, Table 1). Size parameters of the obtained GNPs were also determined by transmission electron microscopy (TEM) using ImageJ software (Fiji): mean diameters were 15.0 ± 1.4 nm ( $n = 185$ ) and 43.5 ± 3.3 nm ( $n = 220$ ). The mass of one nanoparticle was calculated to be 34.1 and 832.2 ag, respectively; and the surface areas were determined to be 707 and 5945 nm<sup>2</sup>.<sup>20,50</sup>

Gold nanorods (GNRs) were synthesised *via* the two-step seed-mediated approach.<sup>31</sup> 2–3 nm seeds were prepared by mixing CTAB (5 mL, 0.20 M), and HAuCl<sub>4</sub> (5 mL, 0.50 mM) with ice-cold NaBH<sub>4</sub> (0.60 mL, 10 mM) whilst intensely stirring at room temperature. After 2 min of vigorous stirring, the solution was left undisturbed at room temperature for 2 hours. For the overgrowth, solutions of HAuCl<sub>4</sub> (50 mL, 1.0 mM) and AgNO<sub>3</sub> (200 μL, 100 mM) were gently mixed with CTAB (50 mL, 0.20 M) at room temperature. After 2 min of stirring, ascorbic acid (550 μL, 100 mM) was added. Next, 120 μL of the seed solution was added under vigorous stirring. After 6 hours the rods were washed with MilliQ to remove the excess CTAB. The average dimensions determined using TEM were 44.0 (±4.0) by 14.8

(±1.9) nm ( $n = 168$ ). The mass of one nanorod was calculated to be 129.8 ag, and the surface area – 2046 nm<sup>2</sup>.

### Peptide and peptide amphiphile synthesis

Peptides and peptide amphiphiles were synthesised by solid-phase peptide synthesis using standard Fmoc-chemistry protocols. The synthesis was performed on an automated microwave peptide synthesiser, Liberty Blue (CEM), using standard settings. All peptides and amphiphiles were synthesised on a Wang resin preloaded with the corresponding C-terminal residue. 20% piperidine in DMF was employed as the deprotection solution, and *N,N'*-diisopropylcarbodiimide (DIC)/OxymaPure (activator/activator base) were used to activate Fmoc-protected α-amino acids. 11-mercaptoundecanoic acid was coupled to the peptide N-terminus using the same protocol as for amino acid coupling but for a longer time (10 min coupling instead of 4 min). The terminal thiol of the acyl chains was blocked with 2,2'-Dithiobis(5-nitropyridine) (DTNP, 1 eq. in DMF, 3 hours). The molecules were cleaved from the resin using a cleavage cocktail comprising 2.5% triisopropylsilane (TIS), 1.5% deionized water, 2.5% phenol in trifluoroacetic acid (TFA, RT, 2 hours). The crude peptide compounds were precipitated into cold diethyl ether, pelleted by centrifugation, redissolved in water, and lyophilised prior to purification. HPLC purification was performed on a Shimadzu system equipped with two LC-20AR pumps, an SPD-20A UV-Vis detector and a Phenomenex Kinetex EVO C18 column (21.2 by 150 mm) with water and acetonitrile as mobile phases. 0.1% TFA was added to the mobile phases, except for purification of the **base** sequence where 0.1% NH<sub>3</sub> was added. Purity of the compounds was confirmed with LC-MS (Fig. S18–S23†). The purified molecules were lyophilised and stored at –20 °C.

### Preparation and characterisation of peptide amphiphile-coated GNPs and GNRs

Coating of the GNPs was performed *via* the ligand exchange procedure as described in detail elsewhere.<sup>30</sup> Briefly, the desired coating molecules were dissolved in DMSO, mixed at a 9 : 1 molar ratio (**base:1** or **base:2**), and added to a stirred GNP suspension. The peptide amphiphile molar excess over the GNPs was at least 200 000. The final concentration of DMSO in the mixture was 50% (v/v). After a 1 hour incubation the samples were centrifuged to pellet the modified GNPs and the supernatants were discarded and replaced with 25% DMSO (v/v). Samples were incubated overnight and after a final centrifugation cycle, the GNPs were dispersed in 5% DMSO. Size exclusion chromatography (SEC, NAP-25 columns, GE Healthcare) was performed with PBS as eluent to remove free ligands and DMSO.

Particle size distributions, determined by dynamic light scattering (DLS), and zeta-potential before and after modification were obtained using a Zetasizer Nano-7 S (Malvern Instruments). The average of three separate measurements was reported. Transmission electron microscopy (TEM) measurements were performed on a JEM 1400 Plus (JEOL) microscope, with an accelerating voltage of 80 kV and with a CDD camera. Sample preparation was as follows: a 10 μL droplet of the



sample was deposited on a carbon-coated copper grid for 20 min. The excess sample was removed by blotting with a fibreless tissue. The grid was washed with MilliQ water once and blotted again. 1% (w/v) uranyl acetate staining was applied, followed by immediate blotting and air drying. UV-vis spectra were recorded in the 900–350 nm range using a Cary 300 UV-vis spectrometer (Agilent). Molar concentrations of GNPs and GNRs were determined by UV-vis using extinction coefficients published by Haiss *et al.*<sup>51</sup> for spherical particles, and by Orendorff *et al.*<sup>52</sup> for rod-like particles.

### Determination of number concentrations of GNPs and GNRs

Gold (Au) mass quantification was conducted using inductively coupled plasma mass spectrometry (ICP-MS) on a PerkinElmer NexION 2000 equipped with a quartz nebulizer and a glass cyclonic spray chamber operating in standard mode (1600 W radio frequency power; 18 mL min<sup>-1</sup> plasma gas flow; 1.2 L min<sup>-1</sup> nebulizer gas flow; and 1.12 L min<sup>-1</sup> auxiliary flow). The peptide amphiphile-coated GNPs or GNRs (in suspension, optical density (OD) ~0.3–0.5) were mixed 1 : 1 (v/v) with *aqua regia* (HNO<sub>3</sub> : HCl = 1 : 3) and were subjected to digestion at 70 °C for 1 hour. Mixtures were diluted 25× times with MilliQ water and directly measured for <sup>197</sup>Au isotope content. Knowing the optical densities of the suspensions before digestion with *aqua regia*, the mass of digested gold, and the calculated mass of one nanoparticle, it was possible to link the OD of GNP or GNR suspensions with their number concentrations. Deviations in the determined gold concentration between the samples with the same core were not significant (Fig. S2†), and could be attributed to incomplete nanoparticle digestion and analysis error, which can lead to deviations of up to 10%.<sup>20</sup>

### Determination of antigen loading displayed onto GNPs and GNRs

Antigen loading was expressed as shown in eqn (1):

$$AL = d_W \times S_{NP} \times N_{NP} \quad (1)$$

where AL is the antigen loading that a GNP or GNR suspension with an OD<sub>LSPR</sub> = 1.0 contains;  $d_W$  is coverage density of a model molecule **W** (see Scheme S1†) displayed on the gold surface;  $S_{NP}$  is the square area of one nanoparticle; and  $N_{NP}$  is the number concentration of nanoparticles in a suspension with OD<sub>LSPR</sub> = 1.0 (determined using ICP-MS, see above).

Coverage density  $d_W$  was determined using UV-vis spectroscopy. Briefly, **base** and **W** peptide amphiphiles were dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, 1.0 mg mL<sup>-1</sup>) and mixed at a molar ratio of 9 : 1. This mixture was diluted with HFIP to obtain a final concentration of **base** of 0.50 mg mL<sup>-1</sup>. Next, it was added to the GNPs and GNRs: for every 0.3 mL of the peptide amphiphile mixture, 0.5 mL of a citrate- or CTAB-protected nanoparticle suspension was taken (OD<sub>519</sub> = 4.5 for 15 nm GNPs, OD<sub>530</sub> = 2.5 for 40 nm GNPs, and OD<sub>756</sub> = 3.2 for GNRs). After a 1 hour incubation with stirring, the nanoparticles were pelleted *via* centrifugation. The pellets were rehydrated with MilliQ water and lyophilised. The dry residue

was redissolved in HFIP and nanoparticles were pelleted again. Both supernatants were analysed to determine concentrations ( $\epsilon_{280}(\mathbf{W}) = 5600 \text{ M}^{-1}\text{cm}^{-1}$ ). Knowing the molar concentrations of GNPs and GNRs and their surface areas, as well as added concentrations of **W**, the following  $d_W$  values were calculated: 0.58 peptide per nm<sup>2</sup> for 15 nm GNPs; 0.35 peptide per nm<sup>2</sup> for 40 nm GNPs; and 0.46 peptide per nm<sup>2</sup> for GNRs. Using a simple proportion based on the molecular weight of OVA<sub>257–264</sub>, and OVA<sub>323–339</sub>, and particle number concentrations obtained using ICP-MS, the coverage densities were recalculated for epitope loading.

### Animals

C57Bl/6, OT-I, and OT-II transgenic mice were purchased from Jackson Laboratory (CA, USA). The animals were bred in-house in agreement with standard laboratory conditions, and provided with water and food *ad libitum*. The animals were treated in compliance with the Dutch government guidelines and the Directive 2010/63/EU of the European Parliament. Experiments were approved by the Ethics Committee for Animal Experiments of Leiden University.

### Bone marrow-derived dendritic cells (BMDCs)

Bone marrow was extracted from tibias, femurs, and thigh bones of C57BL/6 or OT-I/OT-II mice. A single-cell suspension of bone marrow cells was prepared using a 70 µm cell trainer (Greiner Bio-One B.V.). The cell culture medium used for the maturation was DMEM supplemented with 2 mM L-glutamine, 5% (v/v) FCS, 100 U mL<sup>-1</sup> penicillin/streptomycin. Bone marrow cells were seeded in 95 mm Petri dishes at a density of 8–10 × 10<sup>6</sup> cells per dish (Greiner Bio-One B.V.) and incubated at 37 °C and 5% CO<sub>2</sub> for 10 days. Medium was refreshed four times during the 10 day period, 20 ng mL<sup>-1</sup> GM-CSF was added to the medium to induce and maintain the maturation of progenitor cells into BMDCs.

### LDH leakage assay

LDH leakage assay was performed to determine cytotoxicity of the peptide–gold conjugates in BMDCs. For this assay, BMDCs were cultured as described above. After 10 days of culturing, BMDCs (20 × 10<sup>3</sup> per well) were plated in 96-well plates (Greiner Bio-One B.V.) and were exposed to GNPs and GNRs (50 µL per well, 200 µL total well volume) for 4 and 24 hours at 37 °C (5% CO<sub>2</sub>). A negative control (50 µL of PBS) and a positive control (50 µL of the assay lysis buffer) were added to every plate. After the exposure, the plates were centrifuged (1500 rpm, 5 min) and 30 µL of the supernatants were taken for analysis which was performed according to the manufacturer's manual (non-homogenous assay protocol). Cytotoxicity was expressed as the difference between the samples and negative and positive controls (eqn (2)):

$$\text{Cytotoxicity (\%)} = \frac{(A - C)}{(B - C)} \times 100 \quad (2)$$

where  $A$  is the signal arising from the GNP- and GNR-treated wells,  $B$  – the signal from the cell treated with assay lysis



buffer, and  $C -$  is the signal coming from the negative control wells (PBS-treated). Signals were derived from absorbance at 490 nm measured using a microplate reader (infinite 200 PRO Tecan). Every sample was tested in three individual wells. The data shown is an average of three independent experiments ( $N = 3, n = 3$ ).

### GNPs and GNRs uptake by BMDCs

This step was duplicated for two independent experiments: measuring cellular uptake of GNPs and GNRs *via* direct detection of the gold content per cell (ICP-MS assisted) and visualisation of subcellular localisation with TEM analysis. Samples analysed included **15-1**, **15-2**, **40-1**, **40-2**, **Rods-1**, and **Rods-2**. Mature DCs were seeded at a density of  $1 \times 10^6$  cell per well in 6-well plates (Greiner Bio-One B.V.). 250  $\mu$ L of sample (15 nm GNPs – equivalent to  $\approx 500$  nM epitope; 40 nm GNPs – equivalent to  $\approx 125$  nM epitope; GNRs – equivalent to  $\approx 300$  nM epitope in the cell exposure medium) were diluted  $2 \times$  times with DMEM and added to the wells (3 mL total volume). The cells and the samples were incubated for 4 hours at  $37^\circ\text{C}$  (5%  $\text{CO}_2$ ). Next, the cells were washed with PBS (pH 7.2) to remove the non-associated nanoparticles.

For the cell visualisation experiment, a coverslip (Thermanox, 24 mm in diameter, Nunc) was added to each well. The cells were fixed with 2% (v/v) glutaraldehyde, 2% formaldehyde in sodium cacodylate buffer (0.1 M, pH 7.2, 2 hours at room temperature). After fixation, 1% (w/v)  $\text{OsO}_4$  with addition of potassium ferrocyanide (0.8%) was applied for 1 hour at room temperature. Next, the cells were dehydrated through ethanol graded series and embedded into Agar 100 resin (Agar Scientific, AGR1043). Thin sections (70 nm) were cut from the resin using a Leica Ultramicrotome equipped with a diamond knife. The images were acquired on a JEM 1400 Plus microscope, fitted with a CCD camera, at an accelerating voltage of 80 kV. The vesicles dimensions were determined using Fiji ImageJ software. Since vesicles are not completely spherical, each vesicle was measured across its longest and shortest axes, and a mean value was reported in Fig. S5.†

ICP-MS was also used to determine the average gold content per cell. After 4 hours of incubation time, the BMDCs were washed with PBS (pH 7.2,  $3 \times$  times), detached with a cell scraper (Sarstedt) and counted. The cells were lysed with *aqua regia* (1 mL cell sample volume, 1 : 1 dilution, 1 hour at  $70^\circ\text{C}$ ). Lysates were diluted  $25 \times$  times with MilliQ water and directly measured in triplicate using the method described above. Since both the cell numbers and total gold content were known, the average gold content per cell could be calculated (Fig. 3G–I).

### OT-I and OT-II experiments

BMDCs were cultured as described above for 10 days, and pulsed for 4 hours with GNPs, GNRs or controls (PBS or free epitopes) followed by complete removal of the particles from the cell culture. Spleens were removed from OT-I or OT-II mice and strained through a 70  $\mu$ m cell strainer to yield a single-cell suspension. Red blood cells (erythrocytes) were lysed with Ammonium-Chloride-Potassium (ACK) lysis buffer (0.15 M

$\text{NH}_4\text{Cl}$ , 1 mM  $\text{KHCO}_3$ , 0.1 mM  $\text{Na}_2\text{EDTA}$ ; pH 7.3).  $\text{CD8}^+$  or  $\text{CD4}^+$  cells were isolated *via* magnetic separation using a  $\text{CD8}^+$  or  $\text{CD4}^+$  T cell isolation kit according to the supplier's protocol. Enriched T-cell fractions were stained with CFSE-FITC and then added to the plates with BMDCs in the ratio of 3 : 1 = specific T cells:BMDCs in complete RPMI 1640 medium (supplemented with 2 mM glutamine, 5% FCS, 100 U/mL penicillin/streptomycin, and 50  $\mu$ M  $\beta$ -mercaptoethanol). T cells were left to proliferate for 72 hours in the same plates ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ ). Cells were immunostained for Thy1.2, CD4 or CD8, CD25, as well as for viability, and analysed by flow cytometry on a CytoFLEX S (Beckman Coulter). Data analysis was done using the FlowJo software (Treestar). Each experiment was repeated three times ( $N = 3, n = 3$ ), and a representative example is shown in Fig. 4. The gating strategy can be found in Fig. S6.† The proliferation rate was expressed through the  $\text{CD25}^+\text{CFSE-FITC}^{\text{low}}$  cell subset. GraphPad Prism version 7.00 for Windows (GraphPad Software) was used to analyse the data and to plot the dose–response curves.

For the analysis of antigen processing and presentation by BMDCs immunostaining for the full MHC-I/OVA<sub>257–264</sub> complex,  $\text{K}_b\text{-OVA}_{257–264}$ , was used. Mature BMDCs ( $50 \times 10^5$  cell per well in 96-well plates) were exposed to GNPs and GNRs for 4 hours. Cell culture supernatants were removed and half of the wells were analysed directly, and the other half was supplied with fresh medium and analysed after 24 hours. DMEM was used as a negative control, and free OVA<sub>257–264</sub> – as positive one. Flow cytometry was performed on a CytoFLEX S. Data analysis was done using FlowJo software. The gating strategy can be found in Fig. S7.† The data shown is a representative example of two independent experiments ( $N = 2, n = 3$ ).

### Activation of BMDCs

Activation of BMDCs was monitored through cytokine release and upregulation in expression of cellular receptors. Mature BMDCs ( $20 \times 10^5$  cell per well in 96-well plates) were treated with GNPs and GNRs for 24 hours in the same manner as above for the LDH assay. The cell culture supernatants were checked for IL-12 and IL-1 $\beta$  levels. A 'sandwich' ELISA was performed according to a standard protocol at room temperature and involved the following steps: (1) coating the 96-well plates (half area, Costar) with capture antibodies (eBioscience, overnight at  $4^\circ\text{C}$ ); (2) blocking the wells from non-specific interactions by incubation with BSA (2.5% w/v in PBS, 1 hour); (3) incubation (2 hours) with the supernatant of GNP-exposed cells, PBS-treated samples, IL-12 standard at different concentrations, and blank wells (blocking buffer); (4) addition of detection antibodies and complexation with SAV-HRP (1 hour). The readout was based on the reaction of the HRP conjugate with an TMB substrate (BD Bioscience). The reaction was stopped with 1 N  $\text{H}_2\text{SO}_4$  when the blue color in the well became intense. Absorbance at 570 nm was subtracted from absorbance at 450 nm (recorded using a microplate reader Infinite 200 PRO Tecan). Samples from three independent experiments were analysed ( $N = 3, n = 3$ ). For results see Fig. 5A, B and S10–S12.†



Next, mature BMDCs ( $50 \times 10^5$  cell per well in 96-well plates) were exposed to GNPs and GNRs for 4 hours. Cell culture supernatants were removed and half of the wells were analysed directly, and the other half were supplied with fresh medium and analysed after 24 hours. The procedure included immunostaining for CD80, CD86, as well as viability. PBS was used for negative control, and Lipopolysaccharides from *Escherichia coli* (LPS, Sigma-Aldrich) were used for positive control. Flow cytometry was performed on a CytoFLEX S. Data analysis was done using FlowJo software. The gating strategy can be found in Fig. S13.† The data shown is a representative example out of two independent experiments ( $N = 2$ ,  $n = 3$ ).

## Author contributions

Conceptualization, E. A. E., B. S., and A. K.; methodology, E. A. E., G. E. M. L., F. A. M., A. L. B., and B. S.; investigation, E. A. E., G. E. M. L., and F. A. M.; formal analysis, E. A. E., F. A. M., and B. S.; writing – original draft, E. A. E., A. L. B., B. S., and A. K.; writing – review and editing, E. A. E., G. E. M. L., F. A. M., A. L. B., B. S., and A. K.; funding acquisition, E. A. E., B. S., A. K.; resources, B. S., A. K.; supervision, A. L. B., B. S., and A. K.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

E. A. E. acknowledges the financial support of the Global Education Scholarship Program (Russia). B. S. acknowledges funding by Health-Holland, the Dutch Cooperation of Health Foundations (SGF) and the Dutch Heart Foundation, grant numbers LSHM18056-SGF, ERA-CVD2018T092.

## Notes and references

- 1 A. Y. Lin, J. Lunsford, A. S. Bear, J. K. Young, P. Eckels, L. Luo, A. E. Foster and R. A. Drezek, *Nanoscale Res. Lett.*, 2013, **8**, 72.
- 2 K. Niikura, T. Matsunaga, T. Suzuki, S. Kobayashi, H. Yamaguchi, Y. Orba, A. Kawaguchi, H. Hasegawa, K. Kajino, T. Ninomiya, K. Ijiro and H. Sawa, *ACS Nano*, 2013, **7**, 3926–3938.
- 3 N. Climent, I. García, M. Marradi, F. Chiodo, L. Miralles, M. J. Maleno, J. M. Gatell, F. García, S. Penadés and M. Plana, *Nanomedicine*, 2018, **14**, 339–351.
- 4 C. D. Spicer, C. Jumeaux, B. Gupta and M. M. Stevens, *Chem. Soc. Rev.*, 2018, **47**, 3574–3620.
- 5 P. L. Chariou, O. A. Ortega-Rivera and N. F. Steinmetz, *ACS Nano*, 2020, **14**, 2678–2701.
- 6 N. Benne, J. van Duijn, J. Kuiper, W. Jiskoot and B. Slütter, *J. Controlled Release*, 2016, **234**, 124–134.
- 7 P. Foroozandeh and A. A. Aziz, *Nanoscale Res. Lett.*, 2018, **13**, 339.
- 8 B. Rathore, K. Sunwoo, P. Jangili, J. Kim, J. H. Kim, M. Huang, J. Xiong, A. Sharma, Z. Yang, J. Qu and J. S. Kim, *Biomaterials*, 2019, **211**, 25–47.
- 9 T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram, I. F. C. McKenzie and M. Plebanski, *J. Immunol.*, 2004, **173**, 3148–3154.
- 10 L. Xu, X. Wang, W. Wang, M. Sun, W. J. Choi, J.-Y. Kim, C. Hao, S. Li, A. Qu, M. Lu, X. Wu, F. M. Colombari, W. R. Gomes, A. L. Blanco, A. F. de Moura, X. Guo, H. Kuang, N. A. Kotov and C. Xu, *Nature*, 2022, **601**, 366–373.
- 11 F. Campbell, F. L. Bos, S. Sieber, G. Arias-Alpizar, B. E. Koch, J. Huwlyer, A. Kros and J. Bussmann, *ACS Nano*, 2018, **12**, 2138–2150.
- 12 C. M. Goodman, C. D. McCusker, T. Yilmaz and V. M. Rotello, *Bioconjugate Chem.*, 2004, **15**, 897–900.
- 13 G. Sonavane, K. Tomoda and K. Makino, *Colloids Surf., B*, 2008, **66**, 274–280.
- 14 Q. Zhang, V. M. Hitchins, A. M. Schrand, S. M. Hussain and P. L. Goering, *Nanotoxicology*, 2011, **5**, 284–295.
- 15 A. M. Alkilany and C. J. Murphy, *J. Nanopart. Res.*, 2010, **12**, 2313–2333.
- 16 W. H. de Jong, W. I. Hagens, P. Krystek, M. C. Burger, A. J. A. M. Sips and R. E. Geertsma, *Biomaterials*, 2008, **29**, 1912–1919.
- 17 S. Kang, S. Ahn, J. Lee, J. Y. Kim, M. Choi, V. Gujrati, H. Kim, J. Kim, E.-C. Shin and S. Jon, *J. Controlled Release*, 2017, **256**, 56–67.
- 18 X. Xie, J. Liao, X. Shao, Q. Li and Y. Lin, *Sci. Rep.*, 2017, **7**, 3827.
- 19 K. Fytianos, L. Rodriguez-Lorenzo, M. J. D. Clift, F. Blank, D. Vanhecke, C. von Garnier, A. Petri-Fink and B. Rothen-Rutishauser, *Nanomedicine*, 2015, **11**, 633–644.
- 20 F. Abdolapur Monikh, B. Fryer, D. Arenas-Lago, M. G. Vijver, G. Krishna Darbha, E. Valsami-Jones and W. J. G. M. Peijnenburg, *Environ. Sci. Technol. Lett.*, 2019, **6**, 732–738.
- 21 B. D. Chithrani, A. A. Ghazani and W. C. W. Chan, *Nano Lett.*, 2006, **6**, 662–668.
- 22 L. Ding, C. Yao, X. Yin, C. Li, Y. Huang, M. Wu, B. Wang, X. Guo, Y. Wang and M. Wu, *Small*, 2018, **14**, 1801451.
- 23 E. C. Dreaden, A. M. Alkilany, X. Huang, C. J. Murphy and M. A. El-Sayed, *Chem. Soc. Rev.*, 2012, **41**, 2740–2779.
- 24 M. Rabe, C. Aisenbrey, K. Pluhackova, V. de Wert, A. L. Boyle, D. F. Bruggeman, S. A. Kirsch, R. A. Böckmann, A. Kros, J. Raap and B. Bechinger, *Biophys. J.*, 2016, **111**, 2162–2175.
- 25 M. Bhamidipati and L. Fabris, *Bioconjugate Chem.*, 2017, **28**, 449–460.
- 26 C. L. Villiers, H. Freitas, R. Couderc, M.-B. Villiers and P. N. Marche, *J. Nanopart. Res.*, 2010, **12**, 55–60.
- 27 S. Hočevár, A. Milošević, L. Rodriguez-Lorenzo, L. Ackermann-Hirschi, I. Mottas, A. Petri-Fink, B. Rothen-Rutishauser, C. Bourquin and M. J. D. Clift, *ACS Nano*, 2019, **13**, 6790–6800.
- 28 C. Grabinski, N. Schaeublin, A. Wijaya, H. D' Couto, S. H. Baxamusa, K. Hamad-Schifferli and S. M. Hussain, *ACS Nano*, 2011, **5**, 2870–2879.
- 29 B. Halamoda-Kenzaoui, M. Ceridono, P. Urbán, A. Bogni, J. Ponti, S. Gioria and A. Kinsner-Ovaskainen, *J. Nanobiotechnol.*, 2017, **15**, 48.



- 30 E. A. Egorova, M. M. J. van Rijt, N. Sommerdijk, G. S. Gooris, J. A. Bouwstra, A. L. Boyle and A. Kros, *ACS Nano*, 2020, **14**, 5874–5886.
- 31 E. Egorova, G. Arias Alpizar, R. Vlieg, G. S. Gooris, J. Bouwstra, J. van noort, A. Kros and A. L. Boyle, *J. Mater. Chem. B*, 2022, **10**, 1612–1622.
- 32 R. Lévy, N. T. K. Thanh, R. C. Doty, I. Hussain, R. J. Nichols, D. J. Schiffrin, M. Brust and D. G. Fernig, *J. Am. Chem. Soc.*, 2004, **126**, 10076–10084.
- 33 H. Andresen, M. Mager, M. Gießner, P. Charchar, N. Todorova, N. Bell, G. Theocharidis, S. Bertazzo, I. Yarovsky and M. M. Stevens, *Chem. Mater.*, 2014, **26**, 4696–4704.
- 34 Z. Wang, R. Lévy, D. G. Fernig and M. Brust, *Bioconjugate Chem.*, 2005, **16**, 497–500.
- 35 C. Zhao, L. Qiu, P. Lv, A. Han, G. Fang, J. Liu and S. Wang, *Analyst*, 2019, **144**, 1275–1281.
- 36 K. M. Murphy, A. B. Heimberger and D. Y. Loh, *Science*, 1990, **250**, 1720–1723.
- 37 P. M. R. Paulo, P. Zijlstra, M. Orrit, E. Garcia-Fernandez, T. C. S. Pace, A. S. Viana and S. M. B. Costa, *Langmuir*, 2017, **33**, 6503–6510.
- 38 B. D. Chithrani and W. C. W. Chan, *Nano Lett.*, 2007, **7**, 1542–1550.
- 39 H. Hinterwirth, S. Kappel, T. Waitz, T. Prohaska, W. Lindner and M. Lämmerhofer, *ACS Nano*, 2013, **7**, 1129–1136.
- 40 S. Huo, H. Ma, K. Huang, J. Liu, T. Wei, S. Jin, J. Zhang, S. He and X.-J. Liang, *Cancer Res.*, 2013, **73**, 319–330.
- 41 H. G. Hagglund, P. A. McSweeney, G. Mathioudakis, B. Bruno, G. E. Georges, M. J. Gass, P. Moore, G. E. Sale, R. Storb and R. A. Nash, *Transplantation*, 2000, **70**, 1437–1442.
- 42 I. Mäger, K. Langel, T. Lehto, E. Eiríksdóttir and Ü. Langel, *Biochim. Biophys. Acta, Biomembr.*, 2012, **1818**, 502–511.
- 43 E. S. Trombetta and I. Mellman, *Annu. Rev. Immunol.*, 2005, **23**, 975–1028.
- 44 L. Cohn and L. Delamarre, *Front. Immunol.*, 2014, **5**, 255.
- 45 I. W. Hamley, *Bioconjugate Chem.*, 2021, **32**, 1472–1490.
- 46 P. Kalinski, C. M. Hilken, A. Snijders, F. G. Snijdewint and M. L. Kapsenberg, *J. Immunol.*, 1997, **159**, 28–35.
- 47 A. M. Didierlaurent, C. Collignon, P. Bourguignon, S. Wouters, K. Fierens, M. Fochesato, N. Dendouga, C. Langlet, B. Malissen, B. N. Lambrecht, N. Garçon, M. van Mechelen and S. Morel, *J. Immunol.*, 2014, **193**, 1920–1930.
- 48 N. R. G. Assis, A. J. Caires, B. C. Figueiredo, S. B. Morais, F. S. Mambelli, F. v. Marinho, L. O. Ladeira and S. C. Oliveira, *J. Controlled Release*, 2018, **275**, 40–52.
- 49 T. R. Mempel, S. E. Henrickson and U. H. von Andrian, *Nature*, 2004, **427**, 154–159.
- 50 B. C. Mei, E. Oh, K. Susumu, D. Farrell, T. J. Mountziaris and H. Mattoussi, *Langmuir*, 2009, **25**, 10604–10611.
- 51 W. Haiss, N. T. K. Thanh, J. Aveyard and D. G. Fernig, *Anal. Chem.*, 2007, **79**, 4215–4221.
- 52 C. J. Orendorff and C. J. Murphy, *J. Phys. Chem. B*, 2006, **110**, 3990–3994.

